Your browser doesn't support javascript.
Super Dominant Pathobiontic Bacteria in the Nasopharyngeal Microbiota Cause Secondary Bacterial Infection in COVID-19 Patients.
Qin, Tian; Wang, Yajie; Deng, Jianping; Xu, BaoHong; Zhu, Xiong; Wang, Jitao; Zhou, Haijian; Zhao, Na; Jin, Fangfang; Ren, Hongyu; Wang, Huizhu; Li, Qun; Xu, Xinmin; Guo, Yumei; Li, Ruihong; Xiong, Yanwen; Wang, XiaoXia; Guo, Jiane; Zheng, Han; Hou, Xuexin; Wan, Kanglin; Zhang, Jianzhong; Lu, Jinxing; Kan, Biao; Xu, Jianguo.
  • Qin T; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Wang Y; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Deng J; Centers for Disease Control and Prevention of Zigong City, Zigong, China.
  • Xu B; Centers for Disease Control and Prevention of Shijiazhuang City, Shijiazhuang, China.
  • Zhu X; Central and Clinical Laboratory of Sanya People's Hospital, Sanya, China.
  • Wang J; Centers for Disease Control and Prevention of Taiyuan City, Taiyuan, China.
  • Zhou H; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Zhao N; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Jin F; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Ren H; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Wang H; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Li Q; Centers for Disease Control and Prevention of Zigong City, Zigong, China.
  • Xu X; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Guo Y; Centers for Disease Control and Prevention of Shijiazhuang City, Shijiazhuang, China.
  • Li R; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Xiong Y; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Wang X; Central and Clinical Laboratory of Sanya People's Hospital, Sanya, China.
  • Guo J; Centers for Disease Control and Prevention of Taiyuan City, Taiyuan, China.
  • Zheng H; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Hou X; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Wan K; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Zhang J; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Lu J; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Kan B; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
  • Xu J; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing, China.
Microbiol Spectr ; 10(3): e0195621, 2022 06 29.
Article in English | MEDLINE | ID: covidwho-1846337
ABSTRACT
Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease responsible for many infections worldwide. Differences in respiratory microbiota may correlate with disease severity. Samples were collected from 20 severe and 51 mild COVID-19 patients. High-throughput sequencing of the 16S rRNA gene was used to analyze the bacterial community composition of the upper and lower respiratory tracts. The indices of diversity were analyzed. When one genus accounted for >50% of reads from a sample, it was defined as a super dominant pathobiontic bacterial genus (SDPG). In the upper respiratory tract, uniformity indices were significantly higher in the mild group than in the severe group (P < 0.001). In the lower respiratory tract, uniformity indices, richness indices, and the abundance-based coverage estimator were significantly higher in the mild group than in the severe group (P < 0.001). In patients with severe COVID-19, SDPGs were detected in 40.7% of upper and 63.2% of lower respiratory tract samples. In patients with mild COVID-19, only 10.8% of upper and 8.5% of lower respiratory tract samples yielded SDPGs. SDPGs were present in both upper and lower tracts in seven patients (35.0%), among which six (30.0%) patients possessed the same SDPG in the upper and lower tracts. However, no patients with mild infections had an SDPG in both tracts. Staphylococcus, Corynebacterium, and Acinetobacter were the main SDPGs. The number of SDPGs identified differed significantly between patients with mild and severe COVID-19 (P < 0.001). SDPGs in nasopharyngeal microbiota cause secondary bacterial infection in COVID-19 patients and aggravate pneumonia. IMPORTANCE The nasopharyngeal microbiota is composed of a variety of not only the true commensal bacterial species but also the two-face pathobionts, which are one a harmless commensal bacterial species and the other a highly invasive and deadly pathogen. In a previous study, we found that the diversity of nasopharyngeal microbiota was lost in severe influenza patients. We named the genus that accounted for over 50% of microbiota abundance as super dominant pathobiontic genus, which could invade to cause severe pneumonia, leading to high fatality. Similar phenomena were found here for SARS-CoV-2 infection. The diversity of nasopharyngeal microbiota was lost in severe COVID-19 infection patients. SDPGs in nasopharyngeal microbiota were frequently detected in severe COVID-19 patients. Therefore, the SDPGs in nasopharynx microbiota might invade into low respiratory and be responsible for secondary bacterial pneumonia in patients with SARS-CoV-2 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bacterial Infections / Coinfection / Microbiota / COVID-19 Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Microbiol Spectr Year: 2022 Document Type: Article Affiliation country: Spectrum.01956-21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Bacterial Infections / Coinfection / Microbiota / COVID-19 Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Microbiol Spectr Year: 2022 Document Type: Article Affiliation country: Spectrum.01956-21